[Disclosure] Celltrion (068270) Secures European EMA Approval for Phase 3 Clinical Trial Plan Part 1 of ‘CT-P13 SC (Remsima SC)’ in Pediatric Ulcerative Colitis Patients

Fact Source: Financial Supervisory Service (DART) / 2024-06-18

Disclosure Type: Major Management Matters Related to Investment Decisions

💡 3-Second Summary

Celltrion has obtained approval from the European Medicines Agency (EMA) for Part 1 of its global Phase 3 clinical trial plan for ‘CT-P13 SC (Remsima subcutaneous formulation)’ targeting pediatric patients with ulcerative colitis.

📊 1. [Summary of Core Disclosure Content and Major Figures]

• Clinical Trial Title: A randomized, double-blind, Phase 3 clinical trial to evaluate the efficacy and safety of CT-P13 subcutaneous injection (CT-P13 SC) as maintenance therapy in pediatric patients with moderately to severely active ulcerative colitis.
• Clinical Trial Phase & Registration Number: Global Phase 3 trial / EU CT number: 2024-511605-31
• Target Disease (Indication): Moderately to severely active pediatric (ages 6 to 17) ulcerative colitis.
• Submission and Approval Dates:
  • Submission Date: February 27, 2024 (local time)
  • Approval Date: June 17, 2024 (local time)
• Clinical Trial Regulatory Body: European Medicines Agency (EMA)
• Trial Objective: To compare and evaluate the efficacy of low-dose and high-dose CT-P13 subcutaneous injection (CT-P13 SC) maintenance therapy administered every two weeks to achieve clinical remission at week 54.
• Clinical Trial Design and Scale:
  • Total Patients: 243 subjects
  • Treatment Duration: 106 weeks
  • Study Design: Randomized, double-blind, Phase 3 study.
• Future Plans and Key Details:
  • CT-P13 SC is a subcutaneous formulation of Remsima IV (infliximab biosimilar). Celltrion has already completed Phase 3 trials and obtained marketing approval for adult ulcerative colitis and Crohn’s disease in several countries, including the U.S. and Europe. This trial is aimed at expanding the indication to pediatric patients.
  • Under revised European clinical trial regulations, the application and approval process is split into Part 1 (assessment of trial design and methodology) and Part 2 (assessment of trial sites and execution). This disclosure corresponds to the approval of Part 1. Complete approval of Part 2 is required to initiate the trial.

📈 2. [Expert Perspective: What This Disclosure Means for Investors]

• Indication Expansion Process for Pediatric Patients: This disclosure signifies that Celltrion has initiated the first regulatory evaluation phase under European authorities to expand the treatable population of CT-P13 SC to pediatric patients (ages 6 to 17), building on its existing approvals for adults.
• Regulatory Checkpoints of the Two-Part System: Due to European regulatory frameworks, this approval is restricted to ‘Part 1’ (trial design assessment). Since the actual trial cannot begin until ‘Part 2’ (site and operational execution assessment) is approved, investors should monitor the subsequent approval process.
• Inherent Clinical Trial Risks: As stated in the regulatory filing, the statistical probability of an investigational drug receiving final marketing approval is approximately 10%. Results during the approval process may not meet expectations, and the possibility remains that the company may modify or abandon its commercialization plans.
• No Financial Causes Specified: This filing covers a specific regulatory approval stage (Part 1). The disclosure does not contain details regarding financial changes or direct causes of financial performance.

📝 Editor’s Comment (by K-STOCK Editor)

Celltrion’s latest regulatory filing outlines the securing of Part 1 clinical trial approval from the European EMA, which represents an early step in extending the indication of CT-P13 SC to pediatric patients. This step officially begins the regulatory process for broadening the clinical scope of an already approved therapy.

For investors, the crucial variable to track next is the approval of ‘Part 2 (site and operational assessment).’ Because the initiation of patient dosing and clinical investigation depends entirely on receiving Part 2 clearance under European rules, the Part 1 approval alone does not guarantee the immediate launch or ultimate success of the trial. Given the 106-week treatment duration and the statistical 10% probability of final drug approval, a patient and objective observation of the subsequent regulatory milestones is advised.

📢 Disclaimer & Source Information

Source: This content was restructured and newly drafted based on the official submitted data from the Financial Supervisory Service (DART).

Investment Risk Warning: This content is provided solely for informational and linguistic reference purposes. Under no circumstances does it constitute financial advice or a recommendation to buy or sell any specific stock. All investment decisions and financial liabilities rest entirely with the individual investor.

Inquiries: For compliance-related inquiries or copyright requests, please contact ksb220805@gmail.com.